BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Andrikopoulos GK, Pastromas S, Tzeis S. Flecainide: Current status and perspectives in arrhythmia management. World J Cardiol 2015; 7(2): 76-85 [PMID: 25717355 DOI: 10.4330/wjc.v7.i2.76]
URL: https://www.wjgnet.com/1949-8462/full/v7/i2/76.htm
Number Citing Articles
1
Hermann A.M. Mucke. Drug Repurposing Patent Applications January–March 2015ASSAY and Drug Development Technologies 2015; 13(6): 332 doi: 10.1089/adt.2015.29017.patdrrr
2
Michael Sampson. Antiarrhythmic drugs part 2: rhythm-control drugsBritish Journal of Cardiac Nursing 2019; 14(10): 1 doi: 10.12968/bjca.2019.0067
3
Alexandra Smith, Gregg Gerasimon. An electrocardiographic series of flecainide toxicityIndian Pacing and Electrophysiology Journal 2019; 19(2): 75 doi: 10.1016/j.ipej.2018.11.012
4
Alexandra Njegic, Claire Wilson, Elizabeth J. Cartwright. Targeting Ca2 + Handling Proteins for the Treatment of Heart Failure and ArrhythmiasFrontiers in Physiology 2020; 11 doi: 10.3389/fphys.2020.01068
5
Sean P. Gaine, Hugh Calkins. Antiarrhythmic Drug Therapy in Arrhythmogenic Right Ventricular CardiomyopathyBiomedicines 2023; 11(4): 1213 doi: 10.3390/biomedicines11041213
6
G. Andrei Dan. Resurrection of classical antiarrhythmic drugsInternational Journal of Cardiology 2024; 412: 132300 doi: 10.1016/j.ijcard.2024.132300
7
Paola Spitalieri, Rosa V. Talarico, Silvia Caioli, Michela Murdocca, Annalucia Serafino, Marco Girasole, Simone Dinarelli, Giovanni Longo, Sabina Pucci, Annalisa Botta, Giuseppe Novelli, Cristina Zona, Ruggiero Mango, Federica Sangiuolo. Modelling the pathogenesis of Myotonic Dystrophy type 1 cardiac phenotype through human iPSC-derived cardiomyocytesJournal of Molecular and Cellular Cardiology 2018; 118: 95 doi: 10.1016/j.yjmcc.2018.03.012
8
Patrick Connell, Tarah A. Word, Xander H. T. Wehrens. Targeting pathological leak of ryanodine receptors: preclinical progress and the potential impact on treatments for cardiac arrhythmias and heart failureExpert Opinion on Therapeutic Targets 2020; 24(1): 25 doi: 10.1080/14728222.2020.1708326
9
Pei-Chi Yang, Wayne R. Giles, Luiz Belardinelli, Colleen E. Clancy. Mechanisms of flecainide induced negative inotropy: An in silico studyJournal of Molecular and Cellular Cardiology 2021; 158: 26 doi: 10.1016/j.yjmcc.2021.05.007
10
Kathy N. Wright. Small Animal Critical Care Medicine2023; : 961 doi: 10.1016/B978-0-323-76469-8.00177-5
11
Hasan Ashraf, Nway Ko Ko, Vatsal Ladia, Pradyumna Agasthi, Tadhg Prendiville, Fergus O’Herlihy, Sai Harika Pujari, Siva K. Mulpuru, Luis Scott, Dan Sorajja. Use of Flecainide in Stable Coronary Artery Disease: An Analysis of Its Safety in Both Nonobstructive and Obstructive Coronary Artery DiseaseAmerican Journal of Cardiovascular Drugs 2021; 21(5): 563 doi: 10.1007/s40256-021-00483-9
12
Alessandro Zorzi, Alberto Cipriani, Domenico Corrado. Anti-arrhythmic therapy in athletesPharmacological Research 2019; 144: 306 doi: 10.1016/j.phrs.2019.04.027
13
Rachel Lampert, Eugene H. Chung, Michael J. Ackerman, Alonso Rafael Arroyo, Douglas Darden, Rajat Deo, Joe Dolan, Susan P. Etheridge, Belinda R. Gray, Kimberly G. Harmon, Cynthia A. James, Jonathan H. Kim, Andrew D. Krahn, Andre La Gerche, Mark S. Link, Ciorsti MacIntyre, Lluis Mont, Jack C. Salerno, Maully J. Shah. 2024 HRS expert consensus statement on arrhythmias in the athlete: Evaluation, treatment, and return to playHeart Rhythm 2024;  doi: 10.1016/j.hrthm.2024.05.018
14
Fadhel A. Alomar, Chengju Tian, Sean R. Bidasee, Zachary L. Venn, Evan Schroder, Nicholas Y. Palermo, Mohammad AlShabeeb, Benson J. Edagwa, Jason J. Payne, Keshore R. Bidasee. HIV-Tat Exacerbates the Actions of Atazanavir, Efavirenz, and Ritonavir on Cardiac Ryanodine Receptor (RyR2)International Journal of Molecular Sciences 2022; 24(1): 274 doi: 10.3390/ijms24010274
15
Sevilay Goktas Sahoglu, Yusuf Enes Kazci, Erkan Tuncay, Tugce Torun, Celal Akdeniz, Volkan Tuzcu, Esra Cagavi. Functional evaluation of the tachycardia patient‐derived iPSC cardiomyocytes carrying a novel pathogenic SCN5A variantJournal of Cellular Physiology 2022; 237(10): 3900 doi: 10.1002/jcp.30843
16
Enrico Paolini, Giulia Stronati, Federico Guerra, Alessandro Capucci. Flecainide: Electrophysiological properties, clinical indications, and practical aspectsPharmacological Research 2019; 148: 104443 doi: 10.1016/j.phrs.2019.104443
17
Hector Martinez-Navarro, Xin Zhou, Alfonso Bueno-Orovio, Blanca Rodriguez. Electrophysiological and anatomical factors determine arrhythmic risk in acute myocardial ischaemia and its modulation by sodium current availabilityInterface Focus 2021; 11(1): 20190124 doi: 10.1098/rsfs.2019.0124
18
Noah R Schneegurt, Christian Wright, Neil Glenn, Inderpal Thethi. Flecainide-Induced Acute Respiratory Distress Syndrome: A Case ReportCureus 2024;  doi: 10.7759/cureus.61637
19
Wayne A. Ray, Cecilia P. Chung, C. Michael Stein, Walter Smalley, Eli Zimmerman, William D. Dupont, Adriana M. Hung, James R. Daugherty, Alyson L. Dickson, Katherine T. Murray. Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial FibrillationAnnals of Internal Medicine 2023; 176(6): 769 doi: 10.7326/M22-3238
20
Robert C. Klipp, Na Li, Qiongling Wang, Tarah A. Word, Martha Sibrian-Vazquez, Robert M. Strongin, Xander H.T. Wehrens, Jonathan J. Abramson. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2Heart Rhythm 2018; 15(4): 578 doi: 10.1016/j.hrthm.2017.12.017
21
Justin Seltzer, Aaron Schneir. Case Files from the University of California San Diego Medical Toxicology Fellowship: Neonatal Flecainide Toxicity from an Accidental Dosing ErrorJournal of Medical Toxicology 2024; 20(3): 314 doi: 10.1007/s13181-024-01018-9
22
Samuel Lévy. Cardioversion of recent‐onset atrial fibrillation using intravenous antiarrhythmics: A European perspectiveJournal of Cardiovascular Electrophysiology 2021; 32(12): 3259 doi: 10.1111/jce.15264
23
Sukhjinder Chauhan, Desiree Morris, Mina Bhatnagar, Pinak Shah, Dhiraj D Narula. A Rare Case Report of Flecainide-Induced Left Bundle Branch Block (LBBB) and Transient CardiomyopathyCureus 2023;  doi: 10.7759/cureus.37184
24
Carlos E Guzmán, Carla Gabriela Guzmán-Moreno, José Luis Assad-Morell, Edgar Francisco Carrizales-Sepúlveda, Jalaj Garg, Christopher Wong, Markus Bettin, Stefan Simovic, Mariame Chakir. Flecainide toxicity associated with the use of goji berries: a case reportEuropean Heart Journal - Case Reports 2021; 5(6) doi: 10.1093/ehjcr/ytab204
25
Tyson S. Burnham, Heidi T. May, Tami L. Bair, Jeffrey A. Anderson, Brian G. Crandall, Michael J. Cutler, John D. Day, Roger A. Freedman, Kirk U. Knowlton, Joseph B. Muhlestein, Leenhapong Navaravong, Ravi A. Ranjan, Benjamin A. Steinberg, T. Jared Bunch. Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery diseaseAmerican Heart Journal 2022; 243: 127 doi: 10.1016/j.ahj.2021.08.013
26
Hyung Ki Jeong, Sung Soo Kim, Hyun Kuk Kim, Young Jae Ki, Keun Ho Park, Dong Hyun Choi. A case of sinus arrest in atrial fibrillation with pulmonary embolism after flecainide ingestionTranslational and Clinical Pharmacology 2022; 30(4): 182 doi: 10.12793/tcp.2022.30.e19
27
Hannah Wilson, Declan Patton, Zena Moore, Tom O’Connor, Linda Nugent. Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysisEuropean Heart Journal - Cardiovascular Pharmacotherapy 2021; 7(5): 363 doi: 10.1093/ehjcvp/pvaa018
28
Juliia Belikova. THE RELATIONSHIP OF THE RATIO TAURINE/ALANINE IN SERUM AND INDICATORS OF HEART RATE VARIABILITY IN PATIENTS WITH POSTINFARCTION CARDIOSCLEROSIS AND DIABETES MELLITUS TYPE 2The Ukrainian Scientific Medical Youth Journal 2019; 109(1): 6 doi: 10.32345/USMYJ.1(109).2019.6-10
29
Brett J. Wakefield, Anand R. Mehta. Transapical Ablation of Symptomatic Premature Ventricular Contractions in a Patient With Mechanical Mitral and Aortic ValvesJournal of Cardiothoracic and Vascular Anesthesia 2018; 32(6): 2700 doi: 10.1053/j.jvca.2017.12.043
30
H. J. te Kolste, G. J. Kimman, T. Germans, S. A. J. Timmer. Between Scylla and CharybdisNetherlands Heart Journal 2019; 27(7-8): 387 doi: 10.1007/s12471-019-1290-x
31
Deniz Eriş, Feyza Ayşenur Paç. Asymptomatic cardiac tumour with premature ventricular contraction in an athlete: case reportCardiology in the Young 2022; 32(4): 644 doi: 10.1017/S1047951121003334
32
Satoru FUJII. Newly developed atrial fibrillation in the perioperative setting: what to do next?Minerva Anestesiologica 2022; 88(6) doi: 10.23736/S0375-9393.22.16470-9
33
Krisztina Lévay, János Madarász, László Hegedűs. Tuning the chemoselectivity of the Pd-catalysed hydrogenation of pyridinecarbonitriles: an efficient and simple method for preparing pyridyl- or piperidylmethylaminesCatalysis Science & Technology 2022; 12(8): 2634 doi: 10.1039/D1CY02295D
34
EM Sutrisna. Personalized Medicine of flecainide (The Impact of the CYP2D6 and CYP1A2 Polymorphism on Responses to Flecainide)Biomedical and Pharmacology Journal 2024; 17(1): 15 doi: 10.13005/bpj/2830
35
Soroosh Kiani, Michael N. Sayegh, Rand Ibrahim, Neal K. Bhatia, Faisal M. Merchant, Anand D. Shah, Stacy B. Westerman, David B. De Lurgio, Anshul M. Patel, Christine M. Thompkins, Angel R. Leon, Michael S. Lloyd, Mikhael F. El-Chami. The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary DiseaseJACC: Clinical Electrophysiology 2023; 9(7): 1172 doi: 10.1016/j.jacep.2022.12.021
36
Lohit Garg, Manasvi Gupta, Syed Rafay Ali Sabzwari, Sahil Agrawal, Manyoo Agarwal, Talha Nazir, Jeffrey Gordon, Babak Bozorgnia, Matthew W. Martinez. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and managementHeart Failure Reviews 2019; 24(2): 189 doi: 10.1007/s10741-018-9752-6
37
Athanasios Kartalis, Dimitrios Afendoulis, Petros Voutas, Maria Moutafi, Nikolaos Papagiannis, Stefanos Garoufalis, Nikolaos Kartalis, Nikolaos Smyrnioudis, Antonios Ziakas, Matthaios Didagelos. Acute Management of Paroxysmal Atrial Fibrillation with Intravenous Flecainide plus Oral Beta-BlockersInternational Journal of Translational Medicine 2024; 4(2): 334 doi: 10.3390/ijtm4020021
38
Anton Stolear, Maxim Dulgher, Ju Young Bae, Lila Kaminsky, Gini P Jeyashanmugaraja, Uzodinma Emerenini. Wide Spectrum of Flecainide Toxicity: A Case Report and Literature ReviewCureus 2024;  doi: 10.7759/cureus.62923
39
Manish Dwivedi, Sutanu Mukhopadhyay, Shalini Yadav, Kshatresh Dutta Dubey. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposingComputers in Biology and Medicine 2022; 146: 105607 doi: 10.1016/j.compbiomed.2022.105607
40
C. Fielder Camm, A. John Camm. Pathy's Principles and Practice of Geriatric Medicine2022; : 360 doi: 10.1002/9781119484288.ch29
41
K. D. Tiver, D. K. Martin, J. Quah, A. Lahiri, A. N. Ganesan. Failure of diltiazem to prevent 1:1 conduction of atrial flutter: a case reportJournal of Medical Case Reports 2023; 17(1) doi: 10.1186/s13256-023-03947-5
42
N.V. Bezditko. Lixarit — clinical and pharmaceutical aspects of efficacy and safety of flecainide acetate generic drugHYPERTENSION 2022; 14(4): 21 doi: 10.22141/2224-1485.14.4.2021.240254
43
Harold Rivner, Litsa K. Lambrakos. Flecainide Toxicity Leading to Loss of Pacemaker Capture and Cardiac ArrestJACC: Case Reports 2021; 3(4): 586 doi: 10.1016/j.jaccas.2020.11.030
44
Leah Acker, Kristen Bova Campbell, Colleen Naglee, Brad Taicher, Yuriy S. Bronshteyn. Perioperative Management of Flecainide: A Problem-Based Learning DiscussionA&A Practice 2021; 15(4): e01443 doi: 10.1213/XAA.0000000000001443
45
Patryk Klochowicz, Jacek W. Morzycki, Claudia M. Ramírez‐Lozano, Rosa Santillan, Dorota Czajkowska‐Szczykowska. Facile Synthesis of Hydroquinone Linked 3,3’‐Steroid Dimers via a Modified Mitsunobu ProtocolEuropean Journal of Organic Chemistry 2024; 27(25) doi: 10.1002/ejoc.202400309
46
Francesco Moccia, Valentina Brunetti, Teresa Soda, Pawan Faris, Giorgia Scarpellino, Roberto Berra-Romani. Store-Operated Ca2+ Entry as a Putative Target of Flecainide for the Treatment of Arrhythmogenic CardiomyopathyJournal of Clinical Medicine 2023; 12(16): 5295 doi: 10.3390/jcm12165295
47
Muhammad Haris Ilyas, Amaan Mohammad Sharih, Jamila Tukur Jido, Abdul Rahman Zulfiqar Ali, Ava Khoshnaghsh, Mehak Nadeem, Syeda Anum Zahra. Screening for Atrial Fibrillation: Risks, Benefits, and Implications On Future Clinical PracticeCurrent Treatment Options in Cardiovascular Medicine 2024;  doi: 10.1007/s11936-024-01047-1
48
Jonathan W. Waks, Peter Zimetbaum. Antiarrhythmic Drug Therapy for Rhythm Control in Atrial FibrillationJournal of Cardiovascular Pharmacology and Therapeutics 2017; 22(1): 3 doi: 10.1177/1074248416651722
49
Anders Einum, Philip von Brandis, Elisabeth Leirgul, Cathrine Ebbing. Monochorionic Twin Pregnancy Complicated by Arrhythmia in One Twin: Longitudinal Hemodynamic Effects of Flecainide Cardioversion Assessed by Fetal Venous DopplerJournal of Fetal Medicine 2023; 10(03): 116 doi: 10.1055/s-0043-1774753
50
Fernando Wangüemert Pérez, Julio Salvador Hernández Afonso, María del Val Groba Marco, Eduardo Caballero Dorta, Luis Álvarez Acosta, Oscar Campuzano Larrea, Guillermo Pérez, Josep Brugada Terradellas, Ramón Brugada Terradellas. Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular TachycardiaRevista Española de Cardiología (English Edition) 2018; 71(3): 185 doi: 10.1016/j.rec.2017.04.032
51
Isabelle Malhamé, Christy Gandhi, Gofran Tarabulsi, Matthew Esposito, Kristin Lombardi, Antony Chu, Kenneth K Chen. Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardiaObstetric Medicine 2019; 12(2): 66 doi: 10.1177/1753495X18808118
52
Gheorghe-Andrei Dan, Dobromir Dobrev. Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emergingIJC Heart & Vasculature 2018; 21: 11 doi: 10.1016/j.ijcha.2018.08.005
53
Pratik Khatiwada, Lindsey Clark, Arjun Khunger, Bhimesh B Rijal, Jody Ritter. A Case Report of Flecainide Toxicity With Review of LiteratureCureus 2022;  doi: 10.7759/cureus.22261
54
James Boris, Hussein Al-Sudani, Aaron Brophy. Flecainide overdose-induced wide-complex tachyarrhythmia treated with sodium bicarbonate infusionBMJ Case Reports 2024; 17(6): e256391 doi: 10.1136/bcr-2023-256391
55
Giampaolo Morciano, Alessandro Rimessi, Simone Patergnani, Veronica A.M. Vitto, Alberto Danese, Asrat Kahsay, Laura Palumbo, Massimo Bonora, Mariusz R. Wieckowski, Carlotta Giorgi, Paolo Pinton. Calcium dysregulation in heart diseases: Targeting calcium channels to achieve a correct calcium homeostasisPharmacological Research 2022; 177: 106119 doi: 10.1016/j.phrs.2022.106119
56
Chrysovalantou Nikolaidou, Konstantinos Kouskouras, Nikolaos Fragakis, Vassilios P. Vassilikos, Haralambos Karvounis, Theodoros D. Karamitsos. Bolus Intravenous Procainamide in Patients with Frequent Ventricular Ectopics during Cardiac Magnetic Resonance Scanning: A Way to Ensure High Quality ImagingDiagnostics 2021; 11(2): 178 doi: 10.3390/diagnostics11020178
57
Jordi Cano, Esther Zorio, Andrea Mazzanti, Miguel Ángel Arnau, Beatriz Trenor, Silvia G. Priori, Javier Saiz, Lucia Romero. Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 PatientsFrontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.580481
58
Dario Turturiello, Riccardo Cappato. The many NOs to the use of Class IC antiarrhythmics: weren’t the guidelines too strict?European Heart Journal Supplements 2022; 24(Supplement_I): I47 doi: 10.1093/eurheartjsupp/suac073
59
Fernando Wangüemert Pérez, Julio Salvador Hernández Afonso, María del Val Groba Marco, Eduardo Caballero Dorta, Luis Álvarez Acosta, Oscar Campuzano Larrea, Guillermo Pérez, Josep Brugada Terradellas, Ramón Brugada Terradellas. La flecainida reduce las arritmias ventriculares en pacientes con taquicardia ventricular polimórfica catecolaminérgica genotipo RyR2 positivoRevista Española de Cardiología 2018; 71(3): 185 doi: 10.1016/j.recesp.2017.04.014
60
Joachim R. Ehrlich, Christiane Look, Karel Kostev, Carsten W. Israel, Andreas Goette. Impact of dronedarone on the risk of myocardial infarction and stroke in atrial fibrillation patients followed in general practices in GermanyInternational Journal of Cardiology 2019; 278: 126 doi: 10.1016/j.ijcard.2018.11.133
61
Manuel Kraft, Antonius Büscher, Felix Wiedmann, Yannick L’hoste, Walter E. Haefeli, Norbert Frey, Hugo A. Katus, Constanze Schmidt. Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy OptionFrontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.638445
62
GD Singh. “C” Trouble: Class IC Anti-arrhythmic ToxicityJournal of Cardiovascular Medicine and Cardiology 2017; : 033 doi: 10.17352/2455-2976.000047
63
Jennifer A. Ferrante, Muzammel Rizvi, Sami Sakaan, John Eick, B. Tate Cutshall. Consequences of AV blockade omission in flecainide therapyThe Nurse Practitioner 2021; 46(7): 10 doi: 10.1097/01.NPR.0000753872.27819.f7
64
Erind Gjermeni, Andreas Bollmann, Gerhard Hindricks, Andreas Müssigbrodt. Flecainide-Associated Cardiogenic Shock in a Patient with Atrial FibrillationCase Reports in Cardiology 2019; 2019: 1 doi: 10.1155/2019/4820652
65
Bao Hui Poh, Jan Hau Lee, Abdul Alim Abdul Haium, Tze Liang Jonathan Choo. Complete Heart Block Secondary to Flecainide Toxicity: Is It Time for CYP2D6 Genotype Testing?Pediatrics 2020; 146(1) doi: 10.1542/peds.2019-2608